Australia's most trusted
source of pharma news
Posted 18 May 2022 AM
The federal government should reimburse some innovative medicines for cancer and rare diseases before they finish Phase III trials and while HTA processes are still in negotiation, according to a report released by Janssen.
Titled Accelerating Access to Innovative Medicines and prepared for Janssen by Biointelect, the report has recommendations for conditional listing arrangements to provide rapid, reimbursed access to medicines that address areas of high unmet need and have been passed by the TGA provisional pathway.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.